

The Role of Real-World-Evidence in Clinical Research and Regulatory Decision-Making

Shaik Neelofar¹, Kinthada Ramesh²

¹Pharm. D, Student at ClinoSol Research, Hyderabad, Telangana, India

²B. Pharmacy, Student at ClinoSol Research, Hyderabad, Telangana, India

ABSTRACT

In recent years, the utilization of real-world evidence (RWE) has gained prominence as a valuable source of information in the realm of clinical research and regulatory decision-making. This paper explores the multifaceted role that RWE plays in enhancing the understanding of medical products and their effects beyond traditional randomized controlled trials (RCTs). RWE encompasses data derived from various sources, including electronic health records, claims databases, patient registries, and wearable devices. Through the integration of RWE, researchers and regulatory agencies can address questions that may not be feasible or ethical to explore through RCTs alone, providing insights into long-term safety, effectiveness, and real-world outcomes.

KEYWORDS: *real-world evidence, clinical research, regulatory decision-making, electronic health records, randomized controlled trials, safety, effectiveness, patient outcomes*

How to cite this paper: Shaik Neelofar | Kinthada Ramesh "The Role of Real-World-Evidence in Clinical Research and Regulatory Decision-Making" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, pp.821-832, URL: www.ijtsrd.com/papers/ijtsrd59813.pdf



IJTSRD59813

Copyright © 2023 by author (s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (<http://creativecommons.org/licenses/by/4.0>)



I. INTRODUCTION

A. Definition of real-world-evidence (RWE) and its significance in healthcare:

Real world evidence (RWE) is clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real-world-data (RWD).

Real-world-evidence (RWD) are data relating to patient health status and /or the delivery of health care routinely collected from a variety of sources.

Significance of RWE in Healthcare;

Real-world-evidence (RWE) is medical evidence generated during routine patient care. There are multiple sources of RWE, including patient health records, pharmacy claims, registries, and even social media.

RWE can not only help support a product's safe and appropriate use in a post-approval setting, but the data can also inform innovation, trial design, personalized medicine, regulatory filings and optimize decision-making for better patient outcomes. Insights from

real-world-evidence can help care teams understand the disease and help inform treatment decisions. The term "real-world" refers to how patient's interact with the health care system, which can be difficult for researchers to study.

1. Electronic health records (EHRs)
2. Observational studies.
3. Hybrid or pragmatic trails.
4. Health survey's.
5. Patient registries.
6. Administrative and claims databases.

B. Evolution of RWE and its increasing importance in Clinical Research:

FDA has a long history of using what we currently call real-world evidence (RWE) to monitor and evaluate the postmarket safety of approved drugs. RWE has also been used historically to support effectiveness, but on a more limited basis. Advances in the availability and analysis of RWD have increased the potential for generating robust RWE to support FDA regulatory decisions.

FDA is committed to realizing the full potential of fit-for-purpose RWD to generate RWE that will advance the development of therapeutic products and strengthen regulatory oversight of medical products across their lifecycle.

IMPORTANCE OF RWE IN CLINICAL RESEARCH;

Real-world evidence (RWE) is a method of gathering information from a medical records and other sources about how a treatment works in practice. RWE can assist researchers in understanding practical outcomes that go beyond what they see in studies, allowing them to make available. In fact, the FDA employs RWE to aid in making decisions about drug approval or label changes.

This is significant because there are increasingly more drugs that are being approved based on RWE rather than Clinical trial results. One major reason for this is that organizations find it difficult to conduct large, long term studies on real patients with real world conditions.

RWE is gaining importance as a resource to enhance clinical research.

- a. RWD encompasses a vast quantity and variety of raw source data related to patient health status/or healthcare delivery in real-world settings
- b. RWE is the end result of analyzing RWD
- c. RWD and RWE find application throughout the clinical development life cycle, from the NDA(new drug approval) stage through post-market safety monitoring,
- d. Clinical trails are tightly controlled studies to which participants are given specific interventions according to a protocol to evaluate their effects on results.
- e. RWE complements clinical trail data to ensure that a new therapies benefit everyone who requires them
- f. The FDA has methods for obtaining RWE which can aid in drug approval decisions.

An example of RWD are RDAs (research data alliances) which are used to calculate the frequency of drug related adverse events such as infections, blood clots, strokes. They can be used to predict outcomes such as deaths or disability from a heart attack or stroke in patient's with heart disease in some cases.

C. Aim& scope of review article:

In the medical sciences, the importance of review articles is rising. When clinicians want to update their knowledge and generate guidelines about a topic, they frequently use review as a starting point.

“the main fundamental purpose of writing a review is to create a readable synthesis of the best resources available in the literature for an important research question or a current area of research”

Review articles are divided into 2 categories as narrative reviews and systematic reviews. Narrative reviews are written in as easily readable format, and allow consideration of the subject matter within a large spectrum. Systematic review, a very detailed, and comprehensive literature surveying is performed on the selected topic. The simple definition of a review article contains the following key elements:

1. The questions to be dealt with
2. Methods used to find out, and select the best quality researchers so as to respond to these questions.
3. To synthesize available, but quite different researchers

The aims of review article writing are: in their most general form, review papers “are critical evaluations of material that has already been published”. The purpose of and contributions associated with review articles can vary depending on their specific type and research question, but in general, they aim to

- Resolve definitional ambiguities and outline the scope of the topic.
- Provide an integrated, synthesized overview of the current state of knowledge
- Identify inconsistencies in prior results and potential explanations
- Evaluate existing methodological approaches and unique insights.
- Develop conceptual frameworks to reconcile and extend past research.
- Describe research insights, existing gaps, and future research directions.

Scope of article review:

It is also important to determine the precise scope of the literature review. For example,

- What exactly will you cover in your review?
- How comprehensive will it be?
- How long? About how many citation will you use?

Writing and publishing a review can increase your own understanding, contribute to the literature, and advance your research career and status. A good review paper effectively synthesizes the work already done in a scientific field.

II. REAL-WORLD EVIDENCE: TYPES AND SOURCES

RWE can be divided into two types.

1. Primary data: collected specifically for research purposes

2. Secondary data: collected for other purposes such as digital health technologies.

SOURCES:

1. Clinical data; electronic health records, case report forms
2. Patient generated data; health & treatment history, biometric data, patient reported outcomes.
3. cost & utilization data; claims data sets, public data sets
4. public health data; government data sources, national networks and sets.

A. Distinction between RWE and traditional clinical trial data Sources of RWE:

1. Electronic health records (EHRs)

A (EHR) is an electronic version of a patient's medical history, that is maintained by the provider overtime, and may include all the key administration. Clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications.

EHR contain patient-level data collected during and for clinical care. Data with in the electronic health record include diagnostic billing codes, vital signs, laboratory tests results, clinical imaging & physician notes.

2. Claims data from insurance data bases

Claims data also known as administrative data are another sort of electronic record, but on a much bigger scale claims data bases collect information on millions of doctor's appointments, bills, insurance information, and other patient's provider communications.

Data entry outsourced (DEO) provides insurance data entry services for companies who need insurance data enter, digitalized and processed for various purposes such as payments, filings, audits, record keeping and more. The CLUE data base which is run by Lexis Nem, lets insure see any claims that a new coustmor has filled with in the last seven years.

3. Patient registries & disease specific databases

REGISTRIES; A registry is a collection of information about individuals, usually focused around a specific diagnosis or condition.

PATIENT REGISTRIES: are defined as an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves a predetermined scientific, clinical, or policy purpose".

Studies derived from well-designed and well-performed patient registries can provide a real-world

view of clinical practice, patient outcomes, safety, clinical, comparative, and cost effectiveness, and can serve a number of evidence development and decision making purpose.

DISEASE SPECIFIC DATABASES: Gene/disease specific databases are curated, online collections of information on genetic variations in a single gene, gene family or set of genes implicated in a single disease.

Also known as locus specific databases (LSDBs), they provide their information to the scientific community free of charge and with minimal restrictions on how their data can be used, approximately 1800 gene/disease specific databases currently exist.

Gene/disease specific databases have long been recognized as the best way to collect, organize and share information on genetic variation and their effect on patients. This specific databases are also more able to identify and collect the clinical data that are of most use to the researchers and clinics working with these genes and disorders.

4. Mobile health (mHealth) and wearable devices

Mobile health(mHealth) is a general term for the use of mobile phones and other wireless technology in medical care. The most common application of mHealth is the use of mobile devices to educate consumers about preventive healthcare services. It mainly focus on self-monitoring physiological markers relevant to a person's health status and for encouraging physical and healthy diets. The impact of mHealth shows as physical activity, diet changes and knowledge enhancement related to clinical procedures.

The application categories within the mHealth field are;

- Education and awareness
- Helpline
- Diagnostic and treatment support
- Communication and training for healthcare workers
- Disease and epidemic outbreak tracking
- Remote monitoring
- Remote data collection.

WEARABLE DEVICES:

Modern wearable technology falls under a broad spectrum of usability. The origins of wearable technology date back to the 13th century when eyeglasses were first invented. In the 15th century timepieces were created -some of which were small enough to be worn-but it was until the 1960s that the modern wearable technology came into existence. Examples of common wearable technology are smart

jewelry, body-mounted sensors, fitness trackers, smart clothing, AR headsets. The following are the most popular current and next-generation applications of wearable technology are epidermal skin technology, health monitoring, skin temperature sensors, perspiration sensors.

Wearable healthcare technology refers to health monitoring devices worn on the body, such as the wrist, to help monitor the wearer's health data. These devices use biosensors to collect different data from the patient, such as heart rate, blood pressure, sleep patterns and activity.

One of the most important ways wearable technology can be used in healthcare is as a way to monitor patient's health by tracking patient activity and data, this technology can help doctors better understand how their patients are feeling and managing their disease. These are "enabling real-time monitoring, early disease detection and improved patient's outcomes".

5. Social media and online patient communities

social media: digital and social media is a new versatile and peer-reviewed RWE collection methodology, which actually is happening or has happened in the real world. The data is then collected, analysed and published in journals as academic papers. The term social media evidence simply means any data housed within a social platform, like Facebook, LinkedIn or Twitter that needs to be preserved to support litigation.

The analysis of social media is becoming a powerful tool that is being used increasingly to answer research questions across numerous areas including diseases epidemiology, and drug adverse events. Patients are increasingly using web technologies such as social media, blogs, and forums to generate and access opinions of diseases and treatments.

ONLINE PATIENT COMMUNITY: online patient communities are patient-led, online groups where patients, caregivers, doctors, researchers, and others come together with a focus on a particular disease. Examples of online patient communities are. Patients LikeMe HealthBoards, MedHelp, WebMD, Healthunlocked,

Research has shown that when people living with the same chronic illness connect with and learn from each other, ask questions, get referrals, and share tips with other people who personally understand what it's like to live with that illness, health outcomes improve. The five benefits of online patient community are;

- OPCs provide education.
- OPCs provide emotional support.
- OPCs provide other resources.

- OPCs provide information and tools for caregivers.
- OPCs provide a forum for patients, caregivers, and providers to interact.

III. ADVANTAGES AND LIMITATIONS OF REAL-WORLD EVIDENCE

A. ADVANTAGES:

Real-world evidence studies have been used to explore different aspects in health and disease, such as epidemiology, disease burden, treatment patterns, safety, treatment outcomes, long-term outcomes, and patient reported outcomes such as satisfaction, quality of life, medication adherence and patient experience.

a. large-scale and diverse patient population

diverse means differing from one another: unlike people with diverse interests, composed of distinct or unlike elements or qualities. In the medical community, diversity often refers to the inclusion of healthcare professionals, trainees, educators, researchers and patients of varied race, ethnicity, gender, disability, primary spoken language and geographic region. And it builds "rapport with the patient". Learn basic words in your patient's primary language like hello and thank you. Recognize that the patients from diverse backgrounds may have different communication needs. Explain to the patient the different roles performed by people.

Be it the result of a language barrier, differences in philosophy, difference in cultural norms, or even cultural bias, a lack of diversity can lead to a communication breakdown with patients". And when patients cannot fully communicate or express their needs, dangerous mistakes can occur.

b. long-term follow-up and real-world outcomes

as good health is a lifetime issue, long term follow up is an important part of evaluating any medical condition or treatment. This is well appreciated in epidemiologic studies where exposure to a harmful substance is often long term, and its impact on health can appear many years after first occurrence real world outcomes targets original research and definitive reviews regarding the use of real world data to evaluate health outcomes and inform healthcare decision making on drugs, devices and other interventions in clinical practice. The journal includes, but is not limited to, the following research areas: using registries\ databases\health records and other non-selected observational datasets to investigate: drug use and treatment outcomes prescription patterns drug safety signals adherence to treatment guidelines benefit: risk profiles comparative effectiveness economic analyses including cost-of-illness data driven research methodologies, including the capture, curation, search, sharing, analysis and

interpretation of ‘big data’ techniques and approaches to optimize real-world modelling.

c. assessment of treatment effectiveness in routine clinical practice

determining treatment effectiveness once the committee identified the health conditions upon which to focus, it had to determine how to evaluate the effectiveness of treatments for those conditions. There are a number of ways to show that a given treatment is effective in treating a disease or clinical condition. Studies of treatments typically start either with laboratory studies establishing a possible or plausible effect of a treatment or with uncontrolled clinical observations of that effect

B. LIMITATIONS:

a. data quality and completeness

data quality measures how well a dataset meets criteria for accuracy, completeness, validity, consistency, uniqueness, timeliness, and fitness for purpose, and it is critical to all data governance initiatives within an organization.

In basic terms, high quality data should be accurate, timely, complete and actionable-meaning it can be put into use or used to make decisions. To ensure these characteristics are met, it must be relevant and contain the right amount of information for the task at hand. To ensure data quality in field research:

- put a data assurance plan into place. A solid data assurance plan is the bedrock for data quality.
- Run test a head of time
- Train your team
- Improve communication between teams and respondents.
- Implement quality checks.
- Get the right tools to help you monitor your data.

Data completeness refers to the extent to which a dataset has all the relevant and necessary information for a given purpose. A complete dataset should not have any missing, duplicated, or irrelevant values that could effect the analysis.

The challenges of data quality: data quality challenges are the world’s biggest problem today. There are many factors that contribute to these issues, but the two most important ones are “data is not current and data is inconsistent”. When you have outdated data, it can lead to poor decision making and poor business outcomes.

Some examples of limitations include a limited sample size or lack of reliable data such as self-reported, missing data, and deficiencies in data measurements {such as a questionnaire item not asked that could have been used to address a specific issue}

b. potential bias and confounding factors

potential bias arises from any affiliations, funding, or financial holdings that may be viewed as affecting the objectivity of the review. In research, bias occurs when “systematic error introduced into sampling or testing by selecting or encouraging one outcome or answer over others”. Bias can occur at any phase of research, including study design or data collection, as well as in the process of data analysis and publication.

They are ways, however, to try to maintain objectivity and avoid bias with qualitative data analysis:

- use multiple people to code the data.
- have participants review your results.
- Verify with more data resources.
- Check for alternative explanations.
- Review findings with peers.

Limitations; Bias in research can cause distorted results and wrong conclusions. Such studies can lead to unnecessary costs, wrong clinical practice and they can eventually cause some kind of harm to the patient.

Confounding factors are those that may compete with the exposure of interest (eg, treatment) in explaining the outcome of a study. The amount of association “above the beyond” that which can be explained by confounding factors provides a more appropriate estimate of the true association which is due to the exposure.

An example of confounding in real life, a study looking at the association between obesity and heart diseases might be confounded by age, smoking status, diet, and a variety of other risk factors that might be unevenly distributed between the groups being compare

Limitations: there are several methods you can use to decrease the impact of confounding variables on your research:

- Restriction
- Matching
- Statistical control and
- Randomization

In restriction, you restrict your sample by only including certain subjects that have the same values of potential confounding,

Confounding factors may mask an actual association or, more commonly, falsely demonstrate an apparent association between the treatment and outcomes when no real association between them exists.

c. lack of randomization and control randomization: the act or process of ordering or selecting people, things, or or both. in a random way,

as in a sample or experiment, especially in order to reduce the bias and interference by irrelevant variables: randomization was achieved by using a computer-generated number to assign each participant to a group. "randomization prevents biases and makes the results fair".

In nonrandomized designs, intervention assignment is deliberately influenced by the patient or the provider rather than randomly assigned by the researcher. This often results in differences in the baseline characteristics of patient groups receiving different interventions randomization as a method of experimental control has been extensively used in human clinical trials and other biological experiments. It prevents the selection bias and insures against the accidental bias. It produces the comparable groups and eliminates the source of bias in treatment assignments.

Controls allow the experimenter to minimize the effects of factors other than the one being tested. It's how we know an experiment is testing the thing it claims to be testing. This goes beyond science-controls are necessary for any sort of experimental testing, no matter the subject area. **The purpose of a control** when conducting an experiment, a control is an element that remains unchanged or unaffected by other variables is used as a benchmark or a point of comparison against which other test results are measured. Controls are typically used in science experiments, business research, cosmetic testing and medication testing.

A randomized control trial is an experimental form of impact evaluation in which the population receiving the program or policy intervention is chosen at random from the eligible population, and control group is also chosen at random from the same eligible population. Example of randomized control is an active-controlled randomized trial comparing diabetic patients with implanted insulin pumps against diabetic patients who receive multiple insulin injections (control group) randomization avoids bias by eliminating baseline differences in risk between treatment and control groups.

"non experimental research" is research that lacks manipulation of an independent variable, control of extraneous variables through random

Assignment

IV. Real-world evidence in drug development and post-marketing surveillance:

real-world evidence has been used throughout the product lifecycle to inform trial designs, improve clinical guidelines and disease understanding,

facilitate financial discussions and reimbursement decisions, support regulatory decisions, and promote further uses for products already in the market. Real-world evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD.

Post-marketing surveillance uses a number of approaches to monitor drug and device safety. The aim is to continually monitor and evaluate the safety and, in some cases, the efficacy or performance of therapeutic goods that are available on the market and to manage any risks associated with individual products.

a. Use of RWE in pre-approval clinical trails

the use of patient data generated outside of clinical trails and observational studies is known as "real-world evidence" (RWE). RWE has been shown to improve the quality and cost effectiveness of healthcare.

1. Expanded access programs

Sometimes called "compassionate use", expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available

Expanded access may be appropriate when all the following apply:

- Patient has a serious or immediately life-threatening disease or condition
- There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition
- Patient enrollment in a clinical trial is not possible
- Potential patient benefit justifies the potential risks of treatment
- Providing the investigational medical product will not interfere with investigational trials that could support a medical product's development or marketing approval for the treatment indication.

Benefits of expanded access program (EAP) allows physicians and patients access to pre-approval, investigational drugs outside of the clinical trial setting. EAP allow sponsors to provide access to pre-approval products outside of clinical trials.

Three types of expanded access

- Individual patient emergency use
- Intermediate-size patient populations
- Treatment IND treatment protocol- broader patient population.

2. External controls and synthetic control arms

an external control arm is a cohort of control patients that are collected from data external to a single-arm trial. To provide an unbiased estimation of efficacy, the clinical profiles of patients from single and external arms should be aligned, typically using propensity score approaches. There are alternative approaches to infer efficacy based on comparisons between outcomes of single-arm patients and machine-learning predictions of control patient outcomes. These methods include G-computation and Doubly Debiased Machine Learning (DDML) and their evaluation for External Control Arms (ECA) analysis is insufficient.

A synthetic control arm (SCA) is a type of external control that is generated using external patient-level data to improve the interpretation of uncontrolled trials. benefit of synthetic control arms is to “accelerate clinical trial timeliness”. Synthetic control arm can help sponsors ease patient recruitment and retention challenges without compromising the scientific conclusions that can be drawn especially in instances where the standard of care is deemed unacceptable.

a. Post-marketing safety monitoring and signal detection

Post marketing surveillance (PMS) of medication is the process by which marketed medicines are monitored for adverse drug reaction (ADRs) post clinical trials. This surveillance starts ones the drug is approved for market use, after successful clinical trial completion.

Signal detection is the process of actively searching for and identifying safety signals from a wide variety of data sources.

1. Pharmacovigilance and adverse event reporting

Pharmacovigilance is the science and process associated with the detection, evaluation, understanding and prevention of adverse reactions are other problems relating to medicines /medicinal products

Prior to the approval of medicine for use, evidence that it is safe and effective is limited to the results gathered from clinical trails in which patients are carefully selected and carefully monitored under highly controlled conditions. This means that when it is first registered, the medicinal product has been tested on a relatively small number of selected patients for a limited period.

After approval, the medicine can be used by a large number of patients for a long period for a long period of time and in conjunction with other medicinal

products. Under these circumstances some patients may develop certain side effects/adverse reactions.

This is why it is essential to monitor the safety of all medicines for the duration of their use in healthcare.

If you suspect an adverse reaction or want more information about the safety of Novartis medicinal products, please consult your doctor or pharmacist.

Any suspected adverse reactions to our medicinal products can be reported to us by email or by calling our free helpline.

“An adverse reaction is an unfavourable and unintended response to an administered medicinal product”

2. Comparative effectiveness and safety studies

Comparative effectiveness research compares two active forms of treatment or usual care in comparison with usual care with an additional intervention element, comparative effectiveness research differs from study designs that have an inactive control, such a ‘no-intervention’ or placebo group.

The primary purpose of CER is to provide comparative information to the healthcare providers, patients, and policy makers about the standard of care available. This involves research on clinical questions and answered by the explanatory trials during the regulatory approval process.

Example of comparative effectiveness is to compares two or more care options (example treatments, prevention measures, diagnostic tools) to determine which work best, for whom, and in what circumstances. For example, a CER study might compare joint replacement surgery with a new drug in treating severe osteoarthritis of the knee.

Safety is a state in which hazards and conditions leading to physical, psychological or material harm are controlled in order community.

V. Real-world evidence in medical device evaluation

Real-world evidence RWE captured during the testing phase for medical devices and during the post-approval period helps key stakeholders understand the clinical outcomes that can be achieved by using a particular device including by population

For device manufactures, registry data holds strong potential to assist providers making the case for approval of devices and a long term use.

a. Regulatory considerations for medical devices and RWE

FDA’s Center for Devices and Radiological Health(CDRH) is responsible for regulating firms who manufacture, repackage, relabel, and or import

medical devices sold in the United States. In addition, CDRH regulates radiation-emitting electronic products (medical and non-medical) such as lasers, x-ray systems, ultrasound equipment, microwave ovens and color television.

The basic regulatory requirements that manufacturers of medical devices distributed in the U.S. must comply with are:

- Establishment registration
- Medical device listing
- Pre market notification or pre market approval
- Investigational device exemption for clinical studies
- Quality system regulation
- Labeling requirements
- Medical device reporting

Manufacturers must list their devices with the FDA. Establishment required to list their devices include manufacturers, contract manufacturers, contract sterilizers.

To further the efficient and rigorous use of RWE for regulatory decision making, cross country and cross stakeholder. RWE use for regulatory decision making. Further guidance on the design and conduct of innovative clinical trials such as randomized controlled registry studies and other hybrid studies

b. Case studies of medical device approvals based on RWE

c. Incorporating patient-reported outcomes in medical device evaluation

The insights gleaned from patient-reported outcomes (PROs) have implications across the healthcare ecosystem, from clinical investigations to evaluate the safety and effectiveness of medical devices to clinical care and reimbursement decisions.

Thoughtful use of fit-for-purpose PRO instruments to integrate the patient's voice into clinical care paradigms, medical device development, regulatory decisions, and reimbursement and coverage decisions were emphasized throughout the meetings.

A patient-reported outcome (PRO) is any report of the status of a patient's health condition that comes directly from the patient without interpretation of the patient's response by a clinician or anyone else. PROs provide reports from patients about their own health, quality of life, or functional status associated with the health care or treatment they have received. In value-based care, the only true measure of quality are the outcomes that matter to patients. When outcomes are measured and reported, it fosters improvement and adaptation of best practices, thus further improving outcomes.

VI. Regulatory decision-making and RWE acceptance

Real-world evidence (RWE) from studies led by regulators can complement evidence from other sources including clinical trials. RWE can support both pre-authorization and post-approval assessments of EMA's scientific committees, working parties and national competent authorities.

a. Regulatory agencies evolving perspectives on RWE

Even if a drug is successful in a clinical trial and approved by regulators, it is very difficult to guarantee that it is safe and effective on each individual patient. Biochemical and physiologic effects of a drug on patients can be very different because clinical trials are often conducted on a mass patient scale.

The regulatory agencies include Food and Drug Administration and European Medicines Agency, National Medical Products Administration. The momentum is growing and significant steps are taken by regulatory medicine agencies to advance the use of RWE in decision making but challenges persist and collaboratively and embracing change are needed for agencies to evolve to deliver better data-driven decision-making and regulations for patients. Key solutions included establishing a framework for accessing and analyzing RWD through targeted recruitment of experts and training and developing the existing workforce.

b. FDA's framework for real-world evidence

FDA will work with its stakeholders to understand how RWE can best be used to increase the efficiency of clinical research and answer questions that may not have been answered in the trials that lead to the drug approval, for example how a drug works in populations that weren't studied prior to approval.

The framework will include the consideration of the following:

- Whether the RWE are fit for use
- Whether the trial are study design used to generate RWE can provide adequate scientific evidence to answer or help answer the regulatory question
- Whether the study conduct meets FDA regulatory requirements (e.g., for study monitoring and data collection).

Additionally, to efficiently process RWD and submit it for evaluation to FDA, appropriate data standards are necessary. A data standard is a set of rules about how a particular type of data should be structured, defined, formatted, or exchanged between computer

systems. FDA will consider data standards along with the other critical aspects of RWE program.

c. European medicines agencies (EMA) and RWE initiatives

The European Medicines Agency(EMA) protects and promotes human and animal health by evaluating and monitoring medicines within the European Union(EU) and the European Economic Area(EEA). The agency's main responsibilities are authorizing and monitoring medicines in the EU. Companies apply for a single marketing authorization, which is issued by the European commission.

The Agency fulfils its responsibilities by:

- Facilitating the development of medicines & access to them
- Evaluating applications for marketing authorisations
- Monitoring the safety of medicines throughout their lifecycle
- Providing information to healthcare professionals & patients

The EMA's work benefits:

- Patients
- Healthcare professionals
- Academics
- Pharmaceutical companies
- Medicine developers
- Health policymakers

d. Challenges and opportunities in RWE acceptance

Growth in the availability and variety of real-world data, including nonhealthy sources of data, opens up new opportunities, as well as challenges, in their application to real-world evidence and improving health outcomes.

The challenges that must be overcome for better and more widespread use of RWE can be divided into three broad categories: legal and regulatory, technical, and acceptability each of which can be addressed by embracing opportunities for improvement

➤ Challenges:

regulatory legal

- a. data ownership and accessibility
- b. different requirements between countries

Technical

- a. databases that were not designed for research and incomplete or siloed data
- b. high data-input burden for HCPs

Acceptability

- a. Assumptions that data are biased
- b. Resistance to change

➤ Opportunities: legal and regulatory

- a. Adoption of policies to enhance data flow and sharing
- b. interjurisdictional alignment

Technical:

- a. improving IT infrastructure and digital technologies
- b. standardization and facilitation of data input

acceptability

- a. increasing transparency
- b. demonstrating that robust RWE can benefit all stakeholders.

VII. Ethical and privacy considerations in real-world evidence use

Ethical consideration: the EHDS will involve the use of personal health data, raising important ethical consents. For instance, researchers must guarantee that data collection, management and analysis is done transparently and ethically while always safeguarding individuals privacy and confidentiality.

a. Data privacy and patient consent issues

It is well known by digital health technologies have the potential to generate and record a large amount of data, and have the potential to greatly increase the efficiency and effectiveness of healthcare systems. However, how such data is collected, and how it might be used to support regulatory filings for products, continuous to evolve, and in the past, the public and regulators have been sceptical about the quality and security of the data.

Data privacy entails a set of rules and regulations to ensure only authorized individuals and organizations see patient data and medical information. To protect data privacy

- Educate healthcare staff
- Restrict access to data and applications
- Implement data usage controls
- Log and monitor use

Patient consent is the process in which a healthcare provider educates a patient about the risk, benefits and alternatives of a given procedure or intervention. The patient must be competent to make a voluntary decision about whether to undergo the procedure or intervention. Patient consent is important when patients agree to a treatment, they must sign paper work indicating they understand the risk and agreeing doctors can take specific life saving measures if needed. "Patient consent creates trust between doctor and patient by ensuring good understanding".

b. Ensuring data security and confidentiality

Unless the data is irreversibly anonymised or aggregated, RWE contains patients personal health

data. This is a “special” category of personal data and its collection and use is subject to very stringent rules under the General Data Protection Regulation(GDPR). As a general principle, only personal data is necessary, adequate to the research purposes should be collected. The personal data should not be retained longer than what is needed for these purposes and the GDPR rules on security, confidentiality and patients rights must be complied with at all times.

In addition, patients must be informed of why, how, where, when and by whom their personal data retention periods, legal basis for patient rights.

Confidentiality the term ‘confidentiality’ means preserving authorized restrictions on access and disclosure, including means for protecting personal privacy and propriety information. It means that professionals shouldn’t share person; details about some one with others, unless that person has said they can or it’s absolutely necessary. Confidentiality preserves individual dignity, prevents information misuse, and protects autonomous decision making by the patient.

c. Transparency and reproducibility of RWE studies

Transparency of real-world evidence (RWE) studies is critical to understanding how findings of a specific study were derived and is a necessary foundation to assessing validity and determination of whether decisions should be informed by the findings.

We reminded readers of the utility of thinking about emulation of a target trail when planning and communicating about RWE study implementation. The RWE community has recognized lack of transparency as a key barrier to building confidence in RWE study findings and is working with regulators and journal editors to improve the transparency and interpretability of RWE studies.

Reproducibility is the ability to obtain the same results when reanalyzing the original data, following the original analysis strategy. Replicability is the ability to confirm findings in different data and populations

Clinical research is typically evaluated for results or inferential reproducibility, wherein results refers to “corroborating the results of an original study by repeating the original methods in a new set of participants. For the findings of a study to be reproducible means that results obtained by an experiment or an observational study or in a statistical analysis of a data set should be achieved again with a high degree of reliability when the study is replicated.

VIII. Advancements and future directions in real-world evidence

As the healthcare industry focuses increasingly on outcomes, pharma companies are looking to sources beyond randomized clinical trials(RCTs) to measure and demonstrate the value they bring. Real-world evidence (RWE) has been in use for decades, but recent advances in digital and advanced analytics allow it to be employed in new ways. It can help us understand how patient characteristics and behaviors effect health outcomes-thereby helping to predict the progression of a disease, a patient’s responses to a therapy, or the risk of adverse events, for instance-while also increasing the efficiency of R&D investments and accelerating time to market. For any company considering deploying advanced RWE analytics, success will depend on building the right framework and capabilities.

1. Use of advanced analytics and machine learning in RWE analysis

Advanced analytics is a collective term for a wide range of analytics techniques that make use of cutting-edge computing techniques such as machine learning. It employs mathematical and statistical formulas and algorithms to generate new information, recognizes patterns, and also to predict outcomes and their respective probabilities. Since we came clear about this technology, let us understand some of the key benefits of leveraging advanced analytics.

Example of Advanced Analytics in Action

Customer segmentation: identify different groups of customers based on shared characteristics, such as demographics, purchasing behavior, and preferences. This can help them tailor their marketing and sales efforts to better meet the needs of each segment.

We may are may not be aware that machine learning used in various applications like voice search technology image recognition automated translation etc. when we use machine learning in health care you rely on an ever-evolving patient data set. You can use this data to find patterns new diseases, make decision about risks, and predict treatment outcomes.

Applications of machine learning in healthcare are;

- Disease prediction
- Visualization of biomedical data
- Improved diagnosis and disease identification
- More accurate health records
- Personalized treatment options
- Medical research and clinical trial improvement
- Developing medications

2. Integration of RWE with other data sources (e.g., genomics, biomarkers)

Real-world evidence(RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment process

Whole genome sequencing(WGS) and other next generation sequencing(NGS) techniques significantly augment scientific understanding of diseases and how medicines differ in their pharmacological effect from patient to patient. Much like in the clinic, NGS has utility both in clinical research and real-world evidence.

Genetic sequencing is being used in drug development programs to increase the success of clinical trials by honing eligibility criteria based on biomarkers or genetic indicators. Such an approach ensures that physicians prescribe the right drugs to the right patients resulting in better outcomes the first time around.

In RWE data sets, there is a need to understand which biomarkers best correlate with clinical outcomes to facilitate drug development. A substantial difficulty in Real-world settings is that several biomarkers statuses may be missing in the data set, hiding meaningful information in the analysis. Hence, excluding the underline value of missing data may invalidate the results.

3. Potential for real-world data to drive adaptive regulatory approaches

If used and analyzed appropriately, RWD have the potential to generate valid and unbiased RWE with savings in both cost and time, compared to controlled trials, and to enhance the efficiency of medical and health-related research and decision-making. RWD contributes to the development of new therapies by positively influencing the design of clinical trials. Clinical trial stimulation (CTS) traditionally uses virtual populations to test different study designs before the study is conducted with patients.

4. International collaboration and harmonization in RWE

The real-world data studies conducted in the European union, Canada,, and the united states followed extensive dialogue and collaboration was motivated by the perceived benefits of conducting studies.

a. Global efforts to promote the use of RWE in regulatory decisions-making

Real-world evidence(RWE) to support regulatory decision making for product effectiveness has been increasing globally as evident by the increasing number of regulatory frameworks acceptance of

RWE, and guidance documents. However, especially before marketing for regulatory approval, differs across countries. In addition, guidance on the design and conduct of innovative clinical trials, such as randomized controlled registry studies, pragmatic trials, and other hybrid studies

b. Collaborative initiatives among regulatory agencies and stakeholders

IX. Conclusion

In conclusion, the integration of real-world evidence (RWE) into the landscape of clinical research and regulatory decision-making represents a pivotal advancement in our understanding of medical products and their impact on patient health. RWE provides a complementary perspective to traditional randomized controlled trials (RCTs), enabling researchers and regulatory authorities to gain insights into the long-term safety, effectiveness, and real-world outcomes of interventions. The collaborative use of RWE alongside RCTs enhances the robustness and generalizability of evidence, particularly in scenarios where RCTs may be impractical, ethically challenging, or insufficient to address certain questions.

The integration of RWE also underscores the importance of harnessing the vast data sources available in healthcare systems, electronic health records, patient registries, and other real-world settings. However, while RWE offers numerous advantages, it also presents challenges related to data quality, privacy concerns, and methodological rigor. Addressing these challenges is paramount to ensure that RWE contributes meaningfully to regulatory decision-making and clinical research.

X. References

- [1] Hernandez AF, Fleurence RL, Rothman RL. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. *JAMA*. 2017;317(21):2167-2168.
- [2] Sherman RE, Anderson SA, Dal Pan GJ. Real-World Evidence—What Is It and What Can It Tell Us? *New England Journal of Medicine*. 2016;375(23):2293-2297.
- [3] Dreyer NA, Velentgas P, Westrich K. The GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness. *American Journal of Public Health*. 2010;100(9):1477-1482.
- [4] Garrison LP, Neumann PJ, Erickson P. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task

- Force Report. Value in Health. 2007;10(5):326-335.
- [5] Sherman RE, Anderson SA, Pan GJD. Real-world evidence - What is it and what can it tell us? New England Journal of Medicine. 2016; 375:2293-2297.
- [6] Stang PE, Ryan PB, Dusetzina SB. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership. Annals of Internal Medicine. 2010;153(9):600-606.
- [7] FDA. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. U.S. Food and Drug Administration. 2017.

